Syncromune®

Thank you @GRUrology and #IPCU36 attendees for a great meeting! Syncromune's abstract "Effective Resolution of Bone Metastases in Subjects with Metastatic Prostate Cancer Using SYNC-T Therapy SV-102" was presented by Gerald Andriole, M.D. @uropro, Syncromune's Chief Medical Officer, Urology, and can be read here: lnkd.in/gaq8dqXf Syncromune is expanding on these data in the LEGION-100 Phase 2 trial for mCRPC, which is currently enrolling and recruiting trial sites. Visit legion100trial.com to learn more. #ProstateCancer #Syncromune #Immunotherapy #Urology #LEGION100

Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability. SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial. Details: bit.ly/48jYaU5

Today, Syncromune will present new Phase 1 data at #SUO25 highlighting resolution of bone metastases in men with advanced prostate cancer treated with SYNC-T Therapy SV-102. Don’t miss our poster #175 from 4:30-5:30pm MST! bit.ly/48jYaU5

Thanks to everyone who connected with us at #SITC2025! We’re expanding the LEGION-100 trial and welcome new investigator sites interested in advancing in situ combination immunotherapy for prostate cancer. Learn more at legion100trial.com or reach out at info@legion100trial.com #ClinicalResearch #Syncromune

Join Syncromune tomorrow at #SITC2025 to learn how SYNC-T® could redefine the treatment of mCRPC and how your site can be part of the LEGION-100 trial. Learn more about the event and register here: exploresync-t.com #ClinicalTrials #CancerResearch

Heading to #SITC2025? Join us to learn more about the LEGION-100 trial for patients with advanced prostate cancer and how your clinical site could be involved. Learn more at exploresync-t.com

Honored to Attend the 32nd Annual @PCFnews Scientific Retreat! This past weekend, Syncromune had the privilege of attending the 32nd Annual #PCFRetreat25, where some of the brightest minds in prostate cancer research and clinical innovation gathered to share groundbreaking discoveries. We were proud to present Phase 1 data in metastatic prostate cancer, highlighting encouraging results from our combination immunotherapy, SYNC-T Therapy SV-102. We are grateful to be part of such a dedicated community working to accelerate progress for men living with prostate cancer. #ProstateCancer #CancerResearch #Immunotherapy #PCFRetreat2025

Prostate Cancer Awareness Month may be ending, but our commitment to patients and families goes on. 💙 Syncromune is dedicated to advancing new therapies for advanced #ProstateCancer through innovation in immunotherapy. #ProstateCancerAwareness #mCRPC #SYNC_T

We are committed to advancing treatment options for men with mCRPC. Our legion-100 trial is now enrolling. Learn if you or a loved one may qualify: legion100trial.com #ProstateCancerAwareness #mCRPC #ClinicalResearch

1 in 8 men will face prostate cancer in their lifetime. We’re working to bring hope with new immunotherapies for advanced disease. #ProstateCancer #mCRPC #clinicalresearch

Syncromune CEO Eamonn Hobbs joined The BioHub Podcast at #BIO2025 to discuss: ✅ 87% ORR & 53% CR in mCRPC in Phase 1 ✅ Phase 2 LEGION-100 trial ✅ $100M Series A Tune in to hear how we’re innovating immunotherapy for solid tumors: youtube.com/playlist?list=… #ASCO25 #ProstateCancer #Immunotherapy

@Urotoday discussed our recent #ASCO25 data! Our in situ immunotherapy, SYNC-T, demonstrated an 87% ORR and 53% CR in patients with #mCRPC, one of the hardest-to-treat cancers. Read more here: bit.ly/44c7s2p #ProstateCancer #Immunotherapy #mCRPC #ASCO25

Learn how the SYNC-T immunotherapy platform uses a novel approach that synchronizes the location of 3 key components to educate the immune system and activate an anti-cancer response. Dr. Chuck Link joins the Empowered Patient Podcast to talk about SYNC-T™, Syncromune’s in situ immunotherapy for #prostatecancer. Listen now: empoweredpatientradio.com/localized-immu… #biotech #oncology #immunotherapy #CancerResearch #mCRPC #SYNCT

#ASCO25 highlighted groundbreaking and practice-changing studies of immunotherapy, researchers say. Presentations by @charlesrudin of @MSKCancerCenter, Dr Danny Rischin of @PeterMacCC, @anup_kasi of @KUcancercenter, and Dr Ricky Tong of @mainlinehealth. shorturl.at/baqy8

Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program globenewswire.com/news-release/2…

Syncromune Co-Founder, President & CEO, Eamonn Hobbs, has been selected to be a speaker on a panel today at the #BIO2025 International Convention entitled "Translating Nobel Prize Science into the Clinic" at the Boston Convention and Exhibition Center! The panel will take place at 4:15pm ET in room 258A at the Convention. lnkd.in/eA8UbgBp #ProstateCancer

Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025 - 87% ORR - 53% CR - 100% DCR - 14.2 months rPFS - 80% survival after 17.2 month median follow-up globenewswire.com/news-release/2…

It's been an amazing #ASCO25 for Syncromune! Visit us at booth 27167 to learn about becoming a clinical trial site for our Phase 2a LEGION-100 trial for #mCRPC that is now enrolling. legion100trial.com #LEGION100 #ProstateCancer